New hope for Alzheimer's in down syndrome: drug trial launches
NCT ID NCT07636811
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a drug called mivelsiran in 58 adults with Down syndrome who have early-stage Alzheimer's. Participants receive either the drug or a placebo via injection into the spine every few months for two years. The goal is to see if the drug can reduce brain changes linked to Alzheimer's and slow the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
mivelsiran (ALN-APP)
What this could lead to
If successful, this could point toward a treatment that slows or stops Alzheimer's progression in people with Down syndrome.
What could go wrong
This is an early Phase 2 trial with only 58 participants, so results may not apply to everyone. The drug is injected into the spine, which carries risks like infection or headache.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DOWN SYNDROME-ASSOCIATED ALZHEIMER'S DISEASE (DS-AD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Clinical Study Site
Maitland, Florida, 32751, United States
-
Clinical Study Site
Naples, Florida, 34105, United States